Juniper invests in tablet technology for UK site

By Gareth Macdonald

- Last updated on GMT

iStock/Pogonici
iStock/Pogonici

Related tags Clinical trial Pharmaceutical industry Pharmacology

Juniper Pharma Services has invested in a tablet press that can produce 42,000 pills an hour citing customers’ clinical trial supply needs as the driver.

Juniper completed the validation of the RoTab press at its facility in Nottingham, UK this week.

It said the technology is designed to manufacture drug batches in the 50g to 50kg range in a variety of single and bi-layer formats.

A company spokesman told us “the extended capability gives us the scale to meet clients’ demands in later phase clinical trials as opposed to commercial scale​.”

Scale

The largest clinical trial in history – which began in the UK last year​ – is examining the effects of a single daily dose of aspirin on the long term health of 11,000 people who have been diagnosed with early stage cancer. 

In theory, based on our calculations, Juniper’s new tablet press could make the 48,180,000 tablets needed for the full 12-year long study in around 143 days, assuming it was operated for eight hours a day.

With this in mind, we asked if Juniper would consider using the new technology for commercial-scale production.

The firm told us “We could potentially look at projects that involve niche, low-volume licensed tablets in the future but that’s not the driver for this investment​.” 

Expansion

The investment is one of a number Juniper has made in recent months.

Last November​ it bought a Xelodose powder micro-dosing system for the production of Phase I trial materials.

More recently​ Juniper acquired spray drying technology capable of producing 20kg batches and a Becomix homogenizer​ it will use to make topical and semi-solid production for Phase III trials.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars